CD28 and neoplasm: All published relevant methods, to our knowledge, aiming at amplifying in vitro tumor-specific CTLs, including MART-1-specific T cells, are based on the use of autologous antigen presenting cells, allogeneic cells, K562-derived antigen presenting cells or anti-CD3/anti-CD28 beads (14, 17, 44–49).